Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660132 | 0.89 | ALDH1A1 (0.41) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3539696 | 0.83 | MCHR1 (0.40) | MCHR1HRH3 | |
| SCHEMBL856650 | 0.78 | MCHR1 (0.43) | MCHR1HRH3 | |
| SCHEMBL8272498 | 0.78 | MCHR1 (0.43) | MCHR1HRH3 | |
| SCHEMBL8272497 | 0.78 | MCHR1 (0.43) | MCHR1HRH3 | |
| SCHEMBL799469 | 0.78 | MCHR1 (0.43) | MCHR1HRH3 | |
| SCHEMBL4546651 | 0.77 | MCHR1 (0.46) | MCHR1 | |
| SCHEMBL13954231 | 0.77 | MCHR1 (0.46) | MCHR1 | |
| SCHEMBL21592980 | 0.77 | MCHR1 (0.42) | MCHR1HRH3 | |
| SCHEMBL3937932 | 0.77 | MCHR1 (0.42) | MCHR1HRH3PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700638-B2 | 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex | N. V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | N.V. ORGANON (NL) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | GABRB1, GABRA5, GABRB2 | MCHR1 328/4885HRH3 654/4885DRD2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.